Phase I/II study to evaluate the safety and efficacy of intrathecal injection of KP-100IT in subjects with acute spinal cord injury
Phase of Trial: Phase I/II
Latest Information Update: 13 Oct 2016
At a glance
- Drugs KP 100IT (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kringle Pharma
- 05 Oct 2016 Planned End Date changed from 1 Mar 2017 to 1 Oct 2018.
- 05 Oct 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Mar 2018.
- 03 Jul 2014 New trial record